Skip to main content

Sana Biotechnology, Inc. (SANA)

NASDAQ: SANA · IEX Real-Time Price · USD
21.18 0.90 (4.44%)
Oct 26, 2021 4:00 PM EDT - Market closed
Market Cap3.78B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out179.90M
EPS (ttm)-3.98
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume533,948
Open20.16
Previous Close20.28
Day's Range20.04 - 21.47
52-Week Range16.09 - 44.60
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateNov 3, 2021

About SANA

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the tr...

IndustryBiotechnology
IPO DateFeb 4, 2021
Employees321
Stock ExchangeNASDAQ
Ticker SymbolSANA
Full Company Profile

Financial Performance

Financial Statements

News

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology

Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy prog...

Other symbols:BEAM
1 week ago - Benzinga

Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics

Sana Biotechnology has a new $50 million tool in its toolbox.

1 week ago - GeekWire

Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to...

Agreement combines Beam's gene editing technology with Sana's ex vivo platform

1 week ago - GlobeNewsWire

Sana Biotechnology to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its ...

1 month ago - GlobeNewsWire

Sana Biotech To Establish Manufacturing Facility For Gene, Cell Therapy Candidates

Sana Biotechnology Inc (NASDAQ: SANA) has entered into a lease agreement to develop a 163,000 square foot manufacturing facility in Fremont, California.  The facility will support the manufacture of San...

3 months ago - Benzinga

Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Pro...

Facility to Support Allogeneic CAR T, Gene Therapy, and Stem Cell-Derived Therapies

3 months ago - GlobeNewsWire

Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Ste...

First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression

4 months ago - GlobeNewsWire

Sana Biotechnology to Present During Plenary Sessions at ISSCR 2021 Virtual Annual Meeting

SEATTLE , June 14, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be present...

4 months ago - GlobeNewsWire

Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its p...

4 months ago - GlobeNewsWire

Sana Biotechnology Reports First Quarter 2021 Financial Results and Business Updates

Presented key proof of concept data for multiple platforms at AACR 2021

5 months ago - GlobeNewsWire

Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021

— Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes —

5 months ago - GlobeNewsWire

Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021

– Targeted in vivo gene delivery of a CAR using a CD8-specific fusogen results in tumor eradication – – Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in tu...

6 months ago - GlobeNewsWire

Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates

Expects to present data at multiple scientific conferences in 2021

7 months ago - GlobeNewsWire

Regenerative Medicine Attracted Record $20 Billion in Funding in 2020

Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.

7 months ago - GuruFocus

FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell...

MADISON, Wis. and SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, a...

7 months ago - GlobeNewsWire

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at th...

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

8 months ago - PRNewsWire

Sana Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Sh...

SEATTLE, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the closing of its upsized...

8 months ago - GlobeNewsWire

Sana joins Nasdaq with blockbuster $587M IPO

Sana Biotechnology raised $587.

8 months ago - GeekWire

Sana Announces Upsized Pricing of Initial Public Offering

SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of its ...

8 months ago - GlobeNewsWire

Sana Biotechnology boosts IPO range, looks to raise $517 million

Sana Biotechnology — the Seattle upstart that's looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall…

8 months ago - GeekWire

Sana Biotechnology Sets Terms for $323 Million IPO

The Seattle, Wash.-based biotech company says it will raise the funds by offering 15 million shares at $20 to $23 per share.

8 months ago - BioSpace

Secretive Sana, still a year away from the clinic, files for an IPO after a mammoth raise

Sana Biotechnology is following the Moderna playbook to a tee: Promise a lot based on very early science, be vague, nab a major VC raise, then gun for an IPO.

9 months ago - FierceBiotech

Seattle-based Sana Biotechnology aims to raise $150M in IPO

The Seattle-based gene therapy startup filed with the U.S. Securities and Exchange Commission on Wednesday.

9 months ago - Puget Sound Business Journal

Emerging Seattle-Based Sana Biotechnology Seeks to Raise $150 Million IPO

Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company's cell-based therapy discovery and...

9 months ago - BioSpace

Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest...

9 months ago - GeekWire